Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan + Talazoparib in Metastatic Breast Cancer
NCT04039230Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2019
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan, talazoparib in triple-negative breast cancer (TNBC), sponsored by Massachusetts General Hospital. Started Oct 2019; status: active, not recruiting.
02
Drugs
sacituzumab govitecantalazoparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04039230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04039230.